2 research outputs found
Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice
Interventional radiology plays an important and increasing role in cancer treatment. Follow-up is important to be able
to assess treatment success and detect locoregional and distant recurrence and recommendations for follow-up are
needed. At ECIO 2018, a joint ECIO-ESOI session was organized to establish follow-up recommendations for oncologic
intervention in liver, renal, and lung cancer. Treatments included thermal ablation, TACE, and TARE. In total five topics
were evaluated: ablation in colorectal liver metastases (CRLM), TARE in CRLM, TACE and TARE in HCC, ablation in renal
cancer, and ablation in lung cancer. Evaluated modalities were FDG-PET-CT, CT, MRI, and (contrast-enhanced)
ultrasound. Prior to the session, five experts were selected and performed a systematic review and presented
statements, which were voted on in a telephone conference prior to the meeting by all panelists. These statements
were presented and discussed at the ECIO-ESOI session at ECIO 2018. This paper presents the recommendations that
followed from these initiatives. Based on expert opinions and the available evidence, follow-up schedules were
proposed for liver cancer, renal cancer, and lung cancer. FDG-PET-CT, CT, and MRI are the recommended modalities,
but one should beware of false-positive signs of residual tumor or recurrence due to inflammation early after the
intervention. There is a need for prospective preferably multicenter studies to validate new techniques and new
response criteria. This paper presents recommendations that can be used in clinical practice to perform the follow-up
of patients with liver, lung, and renal cancer who were treated with interventional locoregional therapies
Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice
Interventional radiology plays an important and increasing role in cancer treatment. Follow-up is important to be able
to assess treatment success and detect locoregional and distant recurrence and recommendations for follow-up are
needed. At ECIO 2018, a joint ECIO-ESOI session was organized to establish follow-up recommendations for oncologic
intervention in liver, renal, and lung cancer. Treatments included thermal ablation, TACE, and TARE. In total five topics
were evaluated: ablation in colorectal liver metastases (CRLM), TARE in CRLM, TACE and TARE in HCC, ablation in renal
cancer, and ablation in lung cancer. Evaluated modalities were FDG-PET-CT, CT, MRI, and (contrast-enhanced)
ultrasound. Prior to the session, five experts were selected and performed a systematic review and presented
statements, which were voted on in a telephone conference prior to the meeting by all panelists. These statements
were presented and discussed at the ECIO-ESOI session at ECIO 2018. This paper presents the recommendations that
followed from these initiatives. Based on expert opinions and the available evidence, follow-up schedules were
proposed for liver cancer, renal cancer, and lung cancer. FDG-PET-CT, CT, and MRI are the recommended modalities,
but one should beware of false-positive signs of residual tumor or recurrence due to inflammation early after the
intervention. There is a need for prospective preferably multicenter studies to validate new techniques and new
response criteria. This paper presents recommendations that can be used in clinical practice to perform the follow-up
of patients with liver, lung, and renal cancer who were treated with interventional locoregional therapies